Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticová E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH.

J Clin Invest. 2012 Feb;122(2):519-28. doi: 10.1172/JCI59526. Epub 2012 Jan 9.

2.

Hereditary conjugated hyperbilirubinaemia: 37 years later.

Dhumeaux D, Erlinger S.

J Hepatol. 2013 Feb;58(2):388-90. doi: 10.1016/j.jhep.2012.08.025. Epub 2012 Sep 11.

3.

New insights in bilirubin metabolism and their clinical implications.

Sticova E, Jirsa M.

World J Gastroenterol. 2013 Oct 14;19(38):6398-407. doi: 10.3748/wjg.v19.i38.6398. Review.

4.

The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.

Keppler D.

Drug Metab Dispos. 2014 Apr;42(4):561-5. doi: 10.1124/dmd.113.055772. Epub 2014 Jan 23. Review.

5.

Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice.

van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH.

Clin Cancer Res. 2013 Feb 15;19(4):821-32. doi: 10.1158/1078-0432.CCR-12-2080. Epub 2012 Dec 14.

6.

Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.

Iusuf D, Hendrikx JJ, van Esch A, van de Steeg E, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2015 Jan 1;136(1):225-33. doi: 10.1002/ijc.28970. Epub 2014 Jun 3.

7.

Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.

Sticova E, Lodererova A, van de Steeg E, Frankova S, Kollar M, Lanska V, Kotalova R, Dedic T, Schinkel AH, Jirsa M.

Int J Clin Exp Pathol. 2015 May 1;8(5):5252-62. eCollection 2015.

8.

In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.

Durmus S, Naik J, Buil L, Wagenaar E, van Tellingen O, Schinkel AH.

Int J Cancer. 2014 Oct 1;135(7):1700-10. doi: 10.1002/ijc.28797. Epub 2014 Mar 4.

9.

Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.

Chang JH, Plise E, Cheong J, Ho Q, Lin M.

Mol Pharm. 2013 Aug 5;10(8):3067-75. doi: 10.1021/mp4001348. Epub 2013 Jun 21.

PMID:
23750830
10.

Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo.

Durmus S, Lozano-Mena G, van Esch A, Wagenaar E, van Tellingen O, Schinkel AH.

Mol Pharm. 2015 Dec 7;12(12):4259-69. doi: 10.1021/acs.molpharmaceut.5b00453. Epub 2015 Oct 29.

PMID:
26474710
11.

Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, Schinkel AH.

J Clin Invest. 2010 Aug;120(8):2942-52. doi: 10.1172/JCI42168. Epub 2010 Jul 19.

12.

Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.

Higgins JW, Bao JQ, Ke AB, Manro JR, Fallon JK, Smith PC, Zamek-Gliszczynski MJ.

Drug Metab Dispos. 2014 Jan;42(1):182-92. doi: 10.1124/dmd.113.054783. Epub 2013 Nov 5.

13.

Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.

Kunze A, Huwyler J, Camenisch G, Poller B.

Drug Metab Dispos. 2014 Sep;42(9):1514-21. doi: 10.1124/dmd.114.058412. Epub 2014 Jul 2.

14.

Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.

Zimmerman EI, Hu S, Roberts JL, Gibson AA, Orwick SJ, Li L, Sparreboom A, Baker SD.

Clin Cancer Res. 2013 Mar 15;19(6):1458-66. doi: 10.1158/1078-0432.CCR-12-3306. Epub 2013 Jan 22.

15.

Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.

Gozalpour E, Greupink R, Wortelboer HM, Bilos A, Schreurs M, Russel FG, Koenderink JB.

Mol Pharm. 2014 Jun 2;11(6):1844-55. doi: 10.1021/mp400699p. Epub 2014 May 6.

PMID:
24754247
16.

Octreotide inhibits the bilirubin carriers organic anion transporting polypeptides 1B1 and 1B3 and the multidrug resistance-associated protein 2.

Visentin M, Stieger B, Merz M, Kullak-Ublick GA.

J Pharmacol Exp Ther. 2015 Nov;355(2):145-51. doi: 10.1124/jpet.115.227546. Epub 2015 Sep 1.

17.

Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.

Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y.

Drug Metab Dispos. 2006 Jul;34(7):1247-54. Epub 2006 Apr 19.

18.

Loss of OATP1B3 function causes Rotor syndrome: implications for potential use of inhibitors in cancer.

Pratt E, Sissung TM, Figg WD.

Cancer Biol Ther. 2012 Dec;13(14):1374-5. doi: 10.4161/cbt.22010. Epub 2012 Sep 6.

19.

Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel.

de Graan AJ, Lancaster CS, Obaidat A, Hagenbuch B, Elens L, Friberg LE, de Bruijn P, Hu S, Gibson AA, Bruun GH, Corydon TJ, Mikkelsen TS, Walker AL, Du G, Loos WJ, van Schaik RH, Baker SD, Mathijssen RH, Sparreboom A.

Clin Cancer Res. 2012 Aug 15;18(16):4433-40. Epub 2012 Jun 18.

20.

Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.

Lee HH, Leake BF, Teft W, Tirona RG, Kim RB, Ho RH.

Mol Cancer Ther. 2015 Apr;14(4):994-1003. doi: 10.1158/1535-7163.MCT-14-0547. Epub 2015 Feb 18.

Supplemental Content

Support Center